Atlas Trials

Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer

Clinical trial NCT05932667 · TERMINATED

Trial details

NCT number
NCT05932667
Sponsor
Institut Curie
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced or Metastatic Breast Cancer
Start date
2023-10-12
Primary completion
2023-11-24
Enrollment
1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.